The use of p16 in enhancing the histologic classification of uterine smooth muscle tumors

American Journal of Surgical Pathology

Volumn 32, Issue 1, 2008, Pages 98-102

  Atkins, Kristen A ^a,b   Arronte, Nora ^a   Darus, Christopher J ^a   Rice, Laurel W ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Immunohistochemistry; Leiomyoma; Leiomyosarcoma; p16; Uncertain malignant potential; Uterine smooth muscle tumors

Indexed keywords

PROTEIN P16;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; MYOMETRIUM; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; SMOOTH MUSCLE TUMOR OF UNCERTAIN MALIGNANT POTENTIAL; TISSUE MICROARRAY; TUMOR CLASSIFICATION; UTERUS TUMOR;

FEMALE; GENES, P16; HUMANS; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS;

EID: 37549023065     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181574d1e     Document Type: Article

References (17)

1. Andersson S, Hansson B, Norman I, et al. Expression of E6/E7 mRNA from 'high risk' human papillomavirus in relation to CIN grade, viral load and p16INK4a. Int J Oncol. 2006;29:705-711.
2. Amada S, Nakano H, Tsuneyoshi M. Leiomyosarcoma versus bizarre and cellular leiomyomas of the uterus: a comparative study based on the MIB-1 and proliferating cell nuclear antigen indices, p53 expression, DNA flow cytometry, and muscle specific actins. Int J Gynecol Pathol. 1995;14:134-142.
3. Amant F, Moerman P, Vergote I. Report of an unusual problematic uterine smooth muscle neoplasm, emphasizing the prognostic importance of coagulative tumor cell necrosis. Int J Gynecol Cancer. 2005;15:1210-1212.
4. Baird K, Davis S, Antonescu CR, et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res. 2005;65:9226-9235.
5. Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol. 1994;18:535-558.
6. Bodner K, Bodner-Adler B, Czerwenka K et al. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Gynecol Oncol. 2005;96:62-66.
7. Esposito NN, Hunt JL, Bakker A, et al. Analysis of allelic loss as an adjuvant tool in evaluation of malignancy in uterine smooth muscle tumors. Am J Surg Pathol. 2006;30:97-103.
8. Friedrich M, Villena-Heinsen C, Mink D, et al. Leiomyosarcomas of the female genital tract: a clinical and histopathological study. Eur J Gynaecol Oncol. 1998;19:470-475.
9. Gokaslan H, Turkeri L, Kavak ZN, et al. Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors. Gynecol Obstet Invest. 2005;59:36-40.
10. Hall KL, Teneriello MG, Taylor RR, et al. Analysis of ki-ras, p53, mdm2 genes in uterine leiomyomas and leiomyosarcomas. Gynecol Oncol. 1997;65:330-335.
11. Hsu FD, Nielsen TO, Alkushi A, et al. Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. Mod Pathol. 2002;15:1374-1380.
12. Mittal K, Demopoulous RI. Mib-1(Ki67), p53, estrogen receptor and progesterone receptor expression in uterine smooth muscle tumors. Human Pathol. 2001;32:984-987.
13. Niemann TH, Raab SS, Lenel JC, et al. p53 protein overexpression in smooth muscle tumors of the uterus. Hum Pathol. 1995;26:375-379.
14. Quade BJ, Wang TY, Sornberger K, et al. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. Genes Chromosomes Cancer. 2004;40:97-108.
15. Peters WA, Howard DR, Andersen WA, et al. Uterine smooth muscle tumors of uncertain malignant potential. Obstet Gynecol. 1994;83:1015-1020.
16. Skubitz KM, Skubitz AP. Differential gene expression in leiomyosarcoma. Cancer. 2003;98:1029-1038.
17. Zhai YL, Nikaido T, Shiozawa A et al. Expression of cyclins and cyclin dependent kinases in smooth muscle tumors of the uterus. Int J Cancer. 1999;84:244-250.